FUSIONQUANT
Ipsogen
Application Filed: 2003-05-14
Trademark Application Details
CANCELLED - SECTION 8
| Research |
OneLook
Acronym Finder
|
| Serial Number | 78249512 |
| Registration Number | 2930568 |
| Mark Drawing Code | 1000: Typeset: Word(s)/letter(s)/number(s) |
| Cancellation Code | 2 |
| Domestic Representative | Barry L. Kelmachter |
| Attorney Name | Barry L. Kelmachter |
| Attorney Docket Number | 03-383T |
| Law Office Assigned | M20 |
| Employee Name | GRAY, CAROLYN C |
Timeline
| 2003-05-14 | Application Filed |
| 2004-12-14 | Published for Opposition |
| 2005-03-08 | Trademark Registered |
| 2011-03-21 | Location: TMO LAW OFFICE 111 |
| 2015-10-09 | Cancelled |
| 2015-10-09 | Status: Dead/Cancelled |
| 2018-07-08 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  IPSOGEN |
| Address | 2, Boulevard Luce Bat. A Marseille FR 13008 |
| Legal Entity Type | Corporation |
| Legal Entity State | FR |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Diagnostic biological reagents for clinical or medical laboratory use or for determining gene translocations with partner genes which lead to neurological illness, muscular dystrophy, autism, schizophrenia, Down syndrome, leukemia, lymphoma, melanomas of soft parts, liposarcoma, Ewings sarcoma, neuroectodermal tumors, myelodysplastic syndromes, chondrosarcoma, desmoplastic small round cell tumor, rhabdomyosarcoma, non-Hodgkins lymphoma, myeloproliferative disorders, cogenital fibrosarcoma, nephromas, multiple myelomas, parathyroid ademnomes, parathyroid neoplasms, adenomas, lymphoproliferative disorders, plasma cell malignancies, Burkitt lymphoma, meningiomas, dermatofibrosarcoma protuberans, papillary carcinoma, cemento ossifying fibromas of the orbit, orbital neoplasms, ossifying fibromas, salivary gland neoplasms, pleomorphic adenomas, lipomas, hamartomas, uterine neoplasms, leiomyomas, osteosarcomas, cultured tumor cells, neuroblastomas, plasma cell granulomas, papillary renal cell carcinomas, kidney neoplasms, renal cell carcinomas, papillary carcinomas, follicular adenocarcinomas, endometrial neoplasms, follicular lymphomas, glioblastomas, splenic neoplasms, lung neoplasms, squamous cell carcinomas, giant cell fibroblastoma, Bednar tumors, giant cell carcinomas, skin neoplasms, lipoblastomas, ganglioneuroblastomas, breast neoplasms, hypereosinophilic syndrome, synovial sarcoma; pharmaceutical preparations for treatment of muscular dystrophy, autism, schizophrenia, Down syndrome, leukemia, lymphoma, melanomas of soft parts, liposarcoma, Ewings sarcoma, neuroectodermal tumors, myelodysplastic syndromes, chondrosarcoma, desmoplastic small round cell tumor, rhabdomyosarcoma, non-Hodgkins lymphoma, myeloproliferative disorders, cogenital fibrosarcoma, nephromas, multiple myelomas, parathyroid ademnomes, parathyroid neoplasms, adenomas, lymphoproliferative disorders, plasma cell malignancies, Burkitt lymphoma, meningiomas, dermatofibrosarcoma protuberans, papillary carcinoma, cemento ossifying fibromas of the orbit, orbital neoplasms, ossifying fibromas, salivary gland neoplasms, pleomorphic adenomas, lipomas, hamartomas, uterine neoplasms, leiomyomas, osteosarcomas, cultured tumor cells, neuroblastomas, plasma cell granulomas, papillary renal cell carcinomas, kidney neoplasms, renal cell carcinomas, papillary carcinomas, follicular adenocarcinomas, endometrial neoplasms, follicular lymphomas, glioblastomas, splenic neoplasms, lung neoplasms, squamous cell carcinomas, giant cell fibroblastoma, Bednar tumors, giant cell carcinomas, skin neoplasms, lipoblastomas, ganglioneuroblastomas, breast neoplasms, hypereosinophilic syndrome, synovial sarcoma |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| PAPER RECEIVED | 2003-07-23 | 1 MAIL I:Incoming Correspondence |
| CASE FILE IN TICRS | 2003-08-13 | 2 CFIT O:Outgoing Correspondence |
| CASE FILE IN TICRS | 2003-08-13 | 3 CFIT O:Outgoing Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2003-07-23 | 4 CRFA I:Incoming Correspondence |
| APPLICANT AMENDMENT PRIOR TO EXAMINATION - ENTERED | 2003-07-23 | 5 AMPX O:Outgoing Correspondence |
| ASSIGNED TO EXAMINER | 2003-12-04 | 6 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION MAILED | 2003-12-11 | 7 CNRT F:First Action |
| PAPER RECEIVED | 2004-05-28 | 8 MAIL I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2004-05-28 | 9 CRFA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2004-05-28 | 10 CRFA I:Incoming Correspondence |
| LETTER OF SUSPENSION E-MAILED | 2004-06-23 | 11 GNSL S: |
| PAPER RECEIVED | 2004-08-26 | 12 MAIL I:Incoming Correspondence |
| Sec. 1(B) CLAIM DELETED | 2004-08-26 | 13 1.BD I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2004-08-26 | 14 CRFA I:Incoming Correspondence |
| AMENDMENT FROM APPLICANT ENTERED | 2004-09-15 | 15 ACEC I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2004-09-30 | 16 CNSA O:Outgoing Correspondence |
| ASSIGNED TO LIE | 2004-10-06 | 17 ALIE A:Allowance for Publication |
| LAW OFFICE PUBLICATION REVIEW COMPLETED | 2004-10-08 | 18 PREV O:Outgoing Correspondence |
| NOTICE OF PUBLICATION | 2004-11-24 | 19 NPUB O:Outgoing Correspondence |
| PUBLISHED FOR OPPOSITION | 2004-12-14 | 20 PUBO A:Allowance for Publication |
| REGISTERED-PRINCIPAL REGISTER | 2005-03-08 | 21 R.PR A:Allowance for Publication |
| TEAS SECTION 8 & 15 RECEIVED | 2011-03-03 | 22 E815 I:Incoming Correspondence |
| CASE ASSIGNED TO POST REGISTRATION PARALEGAL | 2011-03-18 | 23 APRE A:Allowance for Publication |
| REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | 2011-03-21 | 24 C15A O:Outgoing Correspondence |
| CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9 | 2015-10-09 | 25 CAEX O:Outgoing Correspondence |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 